Cargando…
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was desi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117628/ https://www.ncbi.nlm.nih.gov/pubmed/21695099 http://dx.doi.org/10.4137/CMO.S6085 |